Literature DB >> 19933936

Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study.

Raghava S Velagaleti1, Joseph Massaro, Ramachandran S Vasan, Sander J Robins, William B Kannel, Daniel Levy.   

Abstract

BACKGROUND: The relations of lipid concentrations to heart failure (HF) risk have not been elucidated comprehensively. METHODS AND
RESULTS: In 6860 Framingham Heart Study participants (mean age, 44 years; 54% women) free of baseline coronary heart disease, we related high-density lipoprotein cholesterol (HDL-C) and non-HDL-C to HF incidence during long-term follow-up, adjusting for clinical covariates and myocardial infarction at baseline and updating these at follow-up examinations. We evaluated dyslipidemia-specific population burden of HF by calculating population attributable risks. During follow-up (mean of 26 years), 680 participants (49% women) developed HF. Unadjusted HF incidence in the low (<160 mg/dL) versus high (> or =190 mg/dL) non-HDL-C groups was 7.9% and 13.8%, respectively, whereas incidence in the high (> or =55 [men], > or =65 [women] mg/dL) versus low (<40 [men], <50 [women] mg/dL) HDL-C groups was 6.1% and 12.8%, respectively. In multivariable models, baseline non-HDL-C and HDL-C, modeled as continuous measures, carried HF hazards (confidence intervals) of 1.19 (1.11 to 1.27) and 0.82 (0.75 to 0.90), respectively, per SD increment. In models updating lipid concentrations every 8 years, the corresponding hazards (confidence intervals) were 1.23 (1.16 to 1.31) and 0.77 (0.70 to 0.85). Participants with high baseline non-HDL-C and those with low HDL-C experienced a 29% and 40% higher HF risk, respectively, compared with those in the desirable categories; the population attributable risks for high non-HDL-C and low HDL-C were 7.5% and 15%, respectively. Hazards associated with non-HDL-C and HDL-C remained statistically significant after additional adjustment for interim myocardial infarction.
CONCLUSIONS: Dyslipidemia carries HF risk independent of its association with myocardial infarction, suggesting that lipid modification may be a means for reducing HF risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19933936      PMCID: PMC3600834          DOI: 10.1161/CIRCULATIONAHA.109.830984

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  45 in total

1.  Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet.

Authors:  Y Huang; K E Walker; F Hanley; J Narula; S R Houser; T N Tulenko
Journal:  Circulation       Date:  2003-12-15       Impact factor: 29.690

2.  Risk factors for heart failure in the general population: the study of men born in 1913.

Authors:  H Eriksson; K Svärdsudd; B Larsson; L O Ohlson; G Tibblin; L Welin; L Wilhelmsen
Journal:  Eur Heart J       Date:  1989-07       Impact factor: 29.983

3.  The natural history of congestive heart failure: the Framingham study.

Authors:  P A McKee; W P Castelli; P M McNamara; W B Kannel
Journal:  N Engl J Med       Date:  1971-12-23       Impact factor: 91.245

4.  Changing epidemiological features of cardiac failure.

Authors:  W B Kannel; K Ho; T Thom
Journal:  Br Heart J       Date:  1994-08

5.  Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data.

Authors:  R A Kronmal; K C Cain; Z Ye; G S Omenn
Journal:  Arch Intern Med       Date:  1993-05-10

6.  Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study.

Authors:  W B Kannel; R D Abbott
Journal:  N Engl J Med       Date:  1984-11-01       Impact factor: 91.245

7.  Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

Authors:  J Stamler; D Wentworth; J D Neaton
Journal:  JAMA       Date:  1986-11-28       Impact factor: 56.272

8.  Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase.

Authors:  M I Mackness; S Arrol; C Abbott; P N Durrington
Journal:  Atherosclerosis       Date:  1993-12       Impact factor: 5.162

9.  Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions.

Authors:  J R McNamara; E J Schaefer
Journal:  Clin Chim Acta       Date:  1987-06-30       Impact factor: 3.786

10.  An investigation of coronary heart disease in families. The Framingham offspring study.

Authors:  W B Kannel; M Feinleib; P M McNamara; R J Garrison; W P Castelli
Journal:  Am J Epidemiol       Date:  1979-09       Impact factor: 4.897

View more
  51 in total

Review 1.  Cardiac remodeling at the population level--risk factors, screening, and outcomes.

Authors:  Ola Gjesdal; David A Bluemke; Joao A Lima
Journal:  Nat Rev Cardiol       Date:  2011-10-25       Impact factor: 32.419

2.  Patient perception versus medical record entry of health-related conditions among patients with heart failure.

Authors:  Adnan S Malik; Grigorios Giamouzis; Vasiliki V Georgiopoulou; Lucy V Fike; Andreas P Kalogeropoulos; Catherine R Norton; Dan Sorescu; Sidra Azim; Sonjoy R Laskar; Andrew L Smith; Sandra B Dunbar; Javed Butler
Journal:  Am J Cardiol       Date:  2010-12-22       Impact factor: 2.778

3.  Cholesterol-Lowering Gene Therapy Counteracts the Development of Non-ischemic Cardiomyopathy in Mice.

Authors:  Ilayaraja Muthuramu; Ruhul Amin; Andrey Postnov; Mudit Mishra; Joseph Pierre Aboumsallem; Tom Dresselaers; Uwe Himmelreich; Paul P Van Veldhoven; Olivier Gheysens; Frank Jacobs; Bart De Geest
Journal:  Mol Ther       Date:  2017-08-01       Impact factor: 11.454

4.  Lipid profile and incidence of atrial fibrillation: A prospective cohort study in China.

Authors:  Xintao Li; Lianjun Gao; Zhao Wang; Bo Guan; Xumin Guan; Binhao Wang; Xu Han; Xianjie Xiao; Khalid Bin Waleed; Clarance Chandran; Shouling Wu; Yunlong Xia
Journal:  Clin Cardiol       Date:  2018-03-25       Impact factor: 2.882

Review 5.  Diabetes and the risk of heart failure.

Authors:  Ravi Dhingra; Ramachandran S Vasan
Journal:  Heart Fail Clin       Date:  2011-10-13       Impact factor: 3.179

Review 6.  HDL therapy today: from atherosclerosis, to stent compatibility to heart failure.

Authors:  C R Sirtori; M Ruscica; L Calabresi; G Chiesa; R Giovannoni; J J Badimon
Journal:  Ann Med       Date:  2019 Nov - Dec       Impact factor: 4.709

7.  Successful treatment of established heart failure in mice with recombinant HDL (Milano).

Authors:  Joseph Pierre Aboumsallem; Mudit Mishra; Ruhul Amin; Ilayaraja Muthuramu; Herman Kempen; Bart De Geest
Journal:  Br J Pharmacol       Date:  2018-09-19       Impact factor: 8.739

8.  Recovery of Serum Cholesterol Predicts Survival After Left Ventricular Assist Device Implantation.

Authors:  Amanda R Vest; Peter J Kennel; Dawn Maldonado; James B Young; Maria M Mountis; Yoshifumi Naka; Paolo C Colombo; Donna M Mancini; Randall C Starling; P Christian Schulze
Journal:  Circ Heart Fail       Date:  2016-09       Impact factor: 8.790

9.  Association of lipids with incident heart failure among adults with and without diabetes mellitus: Multiethnic Study of Atherosclerosis.

Authors:  Imo A Ebong; David C Goff; Carlos J Rodriguez; Haiying Chen; Christopher T Sibley; Alain G Bertoni
Journal:  Circ Heart Fail       Date:  2013-03-25       Impact factor: 8.790

10.  Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy.

Authors:  Parin J Patel; Amit V Khera; Robert L Wilensky; Daniel J Rader
Journal:  Eur J Heart Fail       Date:  2013-05-24       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.